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Edited by Lukas HuberAbstract Studies using HeLa cells expressing 5-HT7 receptors
showed that detergent resistant membranous lipid rafts puriﬁed
by sucrose gradient centrifugation contained 5-HT7 receptors
and caveolin-1. Caveolin-1 siRNA-mediated knockdown or sero-
tonin (5-HT) treatment caused signiﬁcant reductions of maxi-
mum [3H]5-HT binding to 5-HT7 receptors and total
immunoreactivity of membranous 5-HT7 receptors in intact cells.
Co-treatment with 5-HT, caveolin-1 siRNA and methyl-b-cyclo-
dextrin had no additive eﬀects on reducing maximum binding of
[3H]5-HT to 5-HT7 receptors. 5-HT-mediated reduction of
[3H]5-HT binding to 5-HT7 receptors was counteracted by gen-
istein, but not by sucrose. Caveolin-1, speciﬁcally localized in
cholesterol-enriched lipid rafts, appears to regulate constitutive
and agonist-stimulated cell surface levels of 5-HT7 receptors
via a clathrin-independent mechanism.
 2007 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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5-HT receptor1. Introduction
The serotonin (5-hydroxytryptamine; 5-HT) neurotransmit-
ter system regulates complex sensory, motor, aﬀective, and
cognitive functions in the brain and smooth muscle tone in
peripheral organs. Fourteen 5-HT receptor subtypes that
mediate actions of 5-HT have been cloned [1]. Based on se-
quence homology and second messenger transduction systems,
they are divided into seven diﬀerent subclasses: 5-HT1A–F, 5-
HT2A–C, 5-HT3, 5-HT4, 5-HT5A–B, 5-HT6 and 5-HT7 recep-
tors. With the exception of the 5-HT3 receptor, which is an
ion channel, all 5-HT receptors are G protein coupled recep-
tors (GPCRs). 5-HT7 receptors (5-HT7R) have a widespread
distribution, both in the central nervous system and in the
periphery [2]. To date there are four known splice variants of
the 5-HT7R which diﬀer in the carboxyl terminal. The 5-
HT7(a), 5-HT7(b) and 5-HT7(d) isoforms are present in humans,
whereas the 5-HT7(a), 5-HT7(b) and 5-HT7(c) are expressed inAbbreviations: 5-HT, 5-hydroxytryptamine, serotonin; 5-MeOT, 5-
metoxytryptamine; GPCR, G protein coupled receptor; Cav-1, cave-
olin-1; siRNA, small interfering RNA; KD, dissociation constant;
MbCD, methyl-b-cyclodextrin
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doi:10.1016/j.febslet.2007.09.059rat [3]. The main physiological functions attributed to 5-
HT7Rs are regulation of mood, circadian rhythmicity and
smooth muscle contraction [4].
The subcellular localization of GPCRs is dynamically regu-
lated. It is known that many GPCRs internalize after pro-
longed stimulation with agonists, via clathrin-coated pits and
endosomes. The receptors can then be recycled to the plasma
membrane or degraded in lysosomes [5]. Several proteins,
including b-arrestins and G proteins coupled kinases, play
important roles in these internalization processes [6,7]. The
mechanism of GPCR internalization has lately undergone
some revision, as it has become clear that some receptors inter-
nalize in a clathrin-independent manner. These traﬃcking pro-
cesses are sensitive to cholesterol depletion, which has led to
the notion that lipid rafts are involved in these processes [8,9].
Lipid rafts consist of highly organized structures of choles-
terol and sphingolipids that cluster receptors and proteins in-
volved in intracellular signaling and protein traﬃcking [10].
Several GPCRs, including B2 bradykinin receptors, M2 mus-
carinic receptors and 5-HT7 receptors, depend on lipid raft
integrity for their proper function [11–13]. Caveolae, a sub-
group of lipid rafts, are ﬂask-shaped invaginations at or near
the plasma membrane that contain caveolin (Cav) proteins
[14]. Of the three known types of Cav proteins, Cav-1 is neces-
sary for maintaining the structure of caveolae. There is emerg-
ing evidence that clathrin-independent receptor internalization
involves caveolae [15].
The aim of this study was to investigate whether Cav-1 lo-
cated in lipid rafts aﬀects 5-HT binding properties of 5-HT7Rs
and 5-HT-regulated receptor localization. The studies were
conducted in HeLa cells stably transfected with human 5-
HT7(A)Rs and endogenously expressing Cav-1.2. Materials and methods
2.1. Cell culture
HeLa cells stably transfected with the human 5-HT7R [3] were main-
tained in Dulbecco’s modiﬁed essential medium (DMEM), containing
4.5 g/L glucose, 2 mM L-glutamine, 25 mM HEPES, 10% fetal bovine
serum (FBS) and 500 lg/ml Geneticin (Invitrogen, Stockholm, Sweden)
at 37 C, 5% CO2/95% air. For sucrose gradient fractionation, cells
were plated in complete medium in 150-mm plates at a density of
200000 cells/ml three days before assay. For MTT viability, binding-
and subcellular fractionation experiments cells were plated in 6-well
or 100 mm plates at a density of 300000 cells/ml one day before assay.
2.2. Cell fractionation by sucrose density gradient centrifugation
Low-density, Triton X-100-insoluble complexes were prepared by a
modiﬁed protocol [16,17]. Two conﬂuent 150-mm plates were washed
with phosphate buﬀered saline (PBS) pH 7.4 and harvested in 10 mMation of European Biochemical Societies.
5116 B. Sjo¨gren, P. Svenningsson / FEBS Letters 581 (2007) 5115–5121Tris pH 7.4, 1 mM EDTA, 1 ll/ml Protease inhibitor Cocktail III (Sig-
ma–Aldrich, Stockholm, Sweden). The cells were homogenized and
centrifuged at 16000 · g, for 20 min, 4 C in a JA-21 rotor. The pellet
was dissolved in 1 ml TX-100 buﬀer (1% Triton X-100 (v/v) (Sigma–
Aldrich) in 25 mM HEPES pH 7.1, 150 mM NaCl) and incubated
on ice for 30 min. The lysate was adjusted to 45% sucrose (90% sucrose
in 25 mM MES (Sigma–Aldrich) pH 6.5, 150 mM NaCl) and a non-
linear gradient (35% and 5% sucrose) was formed above the lysate
and centrifuged at 140000 · g for 24 h, 4 C in an SW-41 rotor. Frac-
tions (650 ll) were taken from the top of the gradient, resulting in 12
fractions. Proteins were extracted with trichloro-acetic acid (TCA)
for 20 min on ice, pelleted by centrifugation at 17000 · g for 20 min,
4 C and dissolved in 1% sodium dodecyl sulphate (SDS). Protein con-
centration was determined with a BCA method (Pierce, Stockholm,
Sweden). Protein (4 lg) from each fraction was subjected to 15%
SDS–poly acrylamide gel electrophoresis (SDS–PAGE) and trans-
ferred to immobilon-P membranes (Millipore, Stockholm, Sweden).
The membranes were blocked for 1 h with 5% (w/v) dry milk in Tris
buﬀered saline-Tween20 (TBS-Tween) pH 7.4, for 2 h at with a pri-
mary antibody against the 5-HT7R (Sigma–Aldrich), Cav-1 (Upstate,
Charlottesville, VA, USA) or Gs (Santa Cruz, CA, USA; all rabbit,
1:500). The membranes were then washed in TBS-Tween, incubated
for 1 h with a secondary horse radish peroxidase (HRP)-coupled
anti-rabbit antibody (Pierce) and washed again in TBS-Tween. The
immunoreactive bands corresponding to 5-HT7, Cav-1 and Gs were de-
tected by chemiluminescence, using ECL reagents (Perkin–Elmer,
Stockholm, Sweden).
2.3. siRNA knockdown of Cav-1 expression
The siRNA sequences were CAV1-1; 5 0-AGACGAGCUGAGCG-
AGAAGCA-30 (sense) and 5 0-UGCUUCUCGCUCAGCUCGUCU-
3 0 (antisense) and CAV1–2; 5 0-CAUCUACAAGCCCAACAAC-30
(sense) and 5 0-GUUGUUGGGCUUGUAGAUG-3 0 (antisense)
(Dharmacon, Stockholm, Sweden). These two Cav-1 siRNA con-
structs were previously veriﬁed [18]. Cells were transfected with
100 nM of each construct at 70% conﬂuency, using Oligofectamine
(Invitrogen) in Optimem without serum and antibiotics. The transfec-
ted cells were split 1:2 in complete medium 24 h after transfection and
harvested for assay after 48 h.2.4. MTT viability assay after Cav-1 siRNA transfection
The cell viability was determined using 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyl-tetrazolium bromide (MTT; Sigma–Aldrich). At the end
of the transfection, MTT was added to the cells to a ﬁnal concentration
of 0.3 mg/ml in PBS. The cells were incubated at 37 C for 1 h, media
removed and the cells lysed and harvested in isopropanol/0.04 M HCl.
The colored reaction was detected at 540 nm and viability expressed as
percent of control without any siRNA.2.5. Treatments
Where indicated, cells were treated with 10 lM 5-HT, 10 mM
methyl-b-cyclodextrin (MbCD), 100 lg/ml Genistein or 0.45 M Su-
crose (all Sigma–Aldrich) for 30 min at 37 C, in DMEM with 0.1%
BSA. The 5-HT treatment occurred in the presence of 10 lM Pargyline
to inhibit the degradation of 5-HT.5-HT7
Gs/olf
Cav-1
121110987654321
Fig. 1. Immunoblots on 5-HT7R, Gs/olf and Cav-1 proteins from
sucrose density gradient fractionation experiments. The opaque band
conﬁned in the 5/35% boundary is located in fractions 4 and 5. Note
that these fractions contain most of the Cav-1 and high levels of the 5-
HT7R as well as Gs/olf, known to be localized in lipid rafts.2.6. Radioligand binding studies on intact cells
Radioligand binding assays on intact Hela-5-HT7R cells were per-
formed as previously described [12], with [3H]5-HT as radioligand
and 10 lM 5-metoxytryptamine (5-MeOT) to deﬁne non-speciﬁc bind-
ing.
2.7. Subcellular fractionation
Cells were washed twice with 5 ml ice-cold PBS pH 7.4, harvested in
300 ll homogenization buﬀer (PBS pH 7.4, 1 ll/ml Protease inhibitor
cocktail III, 10 lM pargyline, 5 mM theophylline), pelleted by centri-
fugation at 3300 · g for 5 min, 4 C and re-suspended in 500 ll homo-
genization buﬀer. The samples were homogenized after which 100 ll
was removed for total protein determination. Nuclei and cell debris
was removed by centrifugation at 1000 · g for 10 min, 4 C. The super-
natant was then centrifuged at 100000 · g for 90 min, 4 C. The pellet,
containing the crude membrane fraction was re-suspended in homog-
enization buﬀer. Total and membrane fraction samples were sonicatedand the protein concentration was determined with a BCA method
(Pierce). Each sample (20 lg) was subjected to separation on a 12%
SDS–PAGE and Western blotting, with antibodies against the 5-
HT7R and Cav-1 as described above.
2.8. Data analyses and statistics
Data from radioligand binding studies were analysed using non-lin-
ear regression in the GraphPad Prism 4 software (GraphPad Prism,
San Diego, CA, USA). Autoradiograms from western blots were quan-
tiﬁed using the NIH Image 1.63 software (NIH, USA). Students’s t-test
or one-way ANOVA followed by Newman–Keul’s post hoc test for
pairwise comparisons were used to evaluate statistical diﬀerences.3. Results
Subcellular localization of 5-HT7Rs and Cav-1 was deter-
mined by TX-100 extraction followed by non-linear sucrose
gradient fractionation. The opaque band in the 5/35% bound-
ary region contained both Cav-1 and 5-HT7Rs (fractions 4–5;
Fig. 1), suggesting that the two proteins are localized in lipid
rafts in these cells. Cav-1 was exclusively found in the deter-
gent insoluble fractions, whereas 5-HT7Rs could be found
both in the detergent insoluble and soluble fractions. The anti-
body against 5-HT7Rs detected two immunoreactive bands.
The lighter molecular weight band probably corresponded to
the monomeric receptor. The heavier molecular weight band
probably corresponded to receptor dimers with more or less
posttranslational modiﬁcations. In non-transfected HeLa cells,
there were no immunoreactive bands towards the 5-HT7R
antibody (data not shown).
To examine whether Cav-1 regulates [3H]5-HT binding to 5-
HT7Rs, previously veriﬁed siRNA oligos against Cav-1 were
used to reduce protein levels of Cav-1 [18]. Using a combina-
tion of two siRNA constructs, targeting diﬀerent parts of the
sequence of Cav-1 mRNA, a reduction of 75% of the Cav-1
protein levels was found 48 h after transfection (Fig. 2A).
The Cav-1 siRNA knockdown had no eﬀect on total 5-
HT7R protein levels (Fig. 2A), but caused a signiﬁcant de-
crease in maximum binding capacity of [3H]5-HT to 5-HT7Rs
in intact cells (Bmax450.0 ± 27.1 fmol/10
6 cells (control),
305.8 ± 26.4 fmol/106 cells (Cav-1 siRNA)) (Fig. 2B). No sig-
niﬁcant change in the KD value of [
3H]5-HT binding to 5-
HT7Rs was found after Cav-1 siRNA knockdown. A non-tar-
geting siRNA construct was used to control for non-speciﬁc ef-
fects. No changes in maximum binding or KD values were
found after transfection with this siRNA construct (Fig. 2C).
An MTT cell viability assay was performed to evaluate possi-
ble toxic eﬀects of siRNA transfections. As shown in Fig. 2D,
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Fig. 2. The eﬀects of Cav-1 siRNA knockdown on [3H]5-HT binding to 5-HT7Rs. (A) The protein levels of Cav-1 were reduced by 75% after Cav-1
siRNA transfection, while the total levels of 5-HT7R was unchanged. ***P < 0.001 with Student’s t-test. (B) Transfection with Cav-1 siRNA
signiﬁcantly (P < 0.05) reduced the maximum [3H]5-HT binding to 5-HT7Rs. Control (n) and Cav-1siRNA (m). (C) Non-targeting siRNA had no
eﬀect on maximum [3H]5-HT binding to 5-HT7Rs. Control (n) and non-targeting siRNA (m). (D) Transfection with siRNA against Cav-1 has no
toxic eﬀect on cell viability as measured by MTT assay.
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viability.
The cells were treated with 5-HT, thoroughly washed and
subjected to a [3H]5-HT radioligand binding assay to investi-
gate cell surface levels of 5-HT7Rs. 5-HT treatment for
30 min caused a signiﬁcant reduction in the Bmax value of
[3H]5-HT binding to 5-HT7Rs (Fig. 3; 762.6 ± 26.5 fmol
bound/106 cells (control) vs. 644.2 ± 39.3 fmol bound/106 cells
(5-HT)). This indicates that the 5-HT7R protein levels at the
cell surface are reduced by 5-HT stimulation. Moreover, the
KD value of [
3H]5-HT binding to 5-HT7Rs was signiﬁcantly in-
creased by 5-HT treatment (8.27 ± 0.99 nM (control) vs.
34.75 ± 4.85 nM (5-HT)), suggesting a shift to a low-aﬃnity
state of the receptors. To investigate whether Cav-1 siRNA
and 5-HT reduced [3H]5-HT binding to 5-HT7Rs via a similar
mechanism, cells were transfected with siRNA against Cav-1,
prior to 5-HT treatment and radioligand binding assays. By
themselves, Cav-1 siRNA (Bmax: 541.0 ± 22.4 fmol/10
6 cells)and 5-HT treatment, reduced the maximum binding of
[3H]5-HT to 5-HT7Rs compared to untreated cells (Fig. 3).
However, when combined, Cav-1 siRNA and 5-HT produced
no additive eﬀect compared to each treatment alone (Fig. 3;
Bmax value 667.4 ± 25.3 fmol/10
6 cells). A similar shift in the
KD value was found in 5-HT treated cells regardless whether
they were transfected with Cav-1 siRNA or not (Fig. 3; KD val-
ues: 9.52 ± 1.31 nM (siRNA); 33.18 ± 2.98 nM (siRNA + 5-
HT)).
To further study the involvement of Cav-1 and 5-HT in reg-
ulating 5-HT7R membrane localization, subcellular fraction-
ation experiments were performed after transfection with
Cav-1 siRNA and/or treatment with 5-HT. Although Cav-1
siRNA knockdown had no eﬀect on the total levels of 5-
HT7R protein (Figs. 2A and 4), the amounts of both mono-
meric (Fig. 4A,B) and dimeric (Fig. 4A,C) 5-HT7Rs in the
membrane fraction were signiﬁcantly reduced. Similarly, treat-
ment with 5-HT signiﬁcantly reduced the amounts of both
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Fig. 4. The eﬀect on membranous 5-HT7R protein levels after 5-HT
treatment and/or Cav-1 siRNA knockdown. (A) Representative
immunoblots of the total and membranous 5-HT7R protein levels
and of total Cav-1 protein levels. (B,C) Quantiﬁed levels of monomeric
(B) or dimeric (C) 5-HT7R protein levels in the membrane fraction.
Treatment with 5-HT or Cav-1 siRNA decreased 5-HT7R protein
levels in the membrane. There was no additive eﬀect of combined 5-HT
and Cav-1 siRNA treatments on membranous expression of 5-HT7Rs.
*P < 0.05; **P < 0.01 versus control using one-way ANOVA followed
by Newman–Keul’s post hoc test.
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Fig. 3. The eﬀect of Cav-1 siRNA knockdown on 5-HT-mediated
regulation of cell surface levels of 5-HT7Rs. The maximum [
3H]5-HT
binding was signiﬁcantly reduced (P < 0.05) by either Cav-1 siRNA
(.) or 5-HT treatment (m) when compared to untreated cells (n). In
cells transfected with Cav-1 siRNA and treated with 5-HT, no further
decrease in maximum [3H]5-HT binding to 5-HT7Rs were found (d).
5-HT treatment signiﬁcantly increased the KD value (P < 0.001)
regardless whether the cells were transfected with Cav-1 siRNA or not.
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5-HT7Rs. No additive eﬀects of Cav-1 siRNA and 5-HT treat-
ment were found on 5-HT7Rs in the membrane fraction
(Fig. 4A–C).
It has previously been shown that the cholesterol sequester-
ing agent MbCD signiﬁcantly decreases maximum [3H]5-HT
binding to 5-HT7Rs [12]. To determine the involvement of cho-
lesterol in 5-HT and Cav-1-mediated regulation of [3H]5-HT
binding to 5-HT7Rs, treatments with 5-HT, MbCD and Cav-
1 siRNA alone or in combinations were performed. 5-HT,
MbCD and Cav-1 siRNA alone signiﬁcantly decreased maxi-
mum [3H]5-HT binding to 5-HT7Rs (Fig. 5A,B; Bmax values:
727.9 ± 20.86 fmol bound/106 cells (control); 519.4 ±
17.38 fmol bound/106 cells (5-HT); 473.4 ± 46.72 fmol bound/
106 cells (MbCD); 556.0 ± 18.37 fmol bound/106 cells (Cav-1
siRNA)). Combined treatment did not result in a further
decrease in maximum [3H]5-HT binding to 5-HT7Rs
(Fig. 5A,B; Bmax values: 433.0 ± 29.80 fmol bound/10
6
cells (5-HT + MbCD); 565.6 ± 19.22 fmol bound/106 cells
(5-HT + Cav-1 siRNA); 548.4 ± 72.71 fmol bound/106 cells
(5-HT + MbCD + Cav-1 siRNA)). These data suggest that
cholesterol and Cav-1 are involved in similar mechanism(s)
underlying constitutive and 5-HT-regulated [3H]5-HT binding
to 5-HT7Rs at the cell surface.
Both Cav-1 and cholesterol are components of lipid rafts. To
further investigate the role of lipid rafts in 5-HT-mediated
reduction of [3H]5-HT binding to 5-HT7R, cells were treated
with genistein, a tyrosine kinase inhibitor and blocker of lipid
raft-mediated internalization [19], prior to radioligand binding
assays. As shown in ﬁgure 6, treatment with genistein had no
eﬀect by itself but could inhibit the 5-HT-mediated reduction
of [3H]5-HT binding to 5-HT7Rs (Fig. 6A,B; Bmax values:
577.5 ± 21.68 fmol bound/106 cells (control); 276.7 ±
33.70 fmol bound/106 cells (5-HT); 643.9 ± 46.01 fmol bound/
106 cells (genistein); 734.7 ± 122.4 fmol bound/106 cells (5-
HT + genistein)).
To examine whether the 5-HT-mediated reduction of [3H]5-
HT binding to 5-HT7R is clathrin-dependent, cells were trea-
ted with sucrose that is known to inhibit clathrin-mediated
endocytosis [20]. Sucrose had no eﬀects on neither constitutivenor 5-HT-mediated reduction of [3H]5-HT binding to 5-
HT7Rs (Fig. 7A,B; Bmax values: 556.0 ± 33.76 fmol bound/
106 cells (control); 211.1 ± 23.16 fmol bound/106 cells (5-HT);
587.7 ± 48.34 fmol bound/106 cells (sucrose); 294.9 ± 19.52
fmol bound/106 cells (5-HT + sucrose)).
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interact, we attempted to perform co-immunoprecipitation
experiments. No evidence for a direct interaction could be de-
tected (data not shown), indicating that 5-HT7Rs is part of a
larger complex bound to Cav-1.4. Discussion
The present study investigated the inﬂuence of Cav-1 on
5-HT binding and cell surface levels of 5-HT7Rs. Sucrose
gradient fractionation showed the presence of both 5-HT7Rs
and Cav-1 in the detergent insoluble fractions. In our HeLa
cell system, Cav-1 was only present in the lighter fractions
of the density gradient, most likely corresponding to caveo-
lin-containing caveolae. 5-HT7Rs were also found in heavier
fractions, indicating the presence in multiple membranous
and intracellular compartments. Nonetheless, siRNA-medi-
ated knockdown of Cav-1 resulted in reduced maximum
binding of [3H]5-HT to 5-HT7Rs and reduced membranous
5-HT7R immunoreactivity without inﬂuencing the total lev-
els of 5-HT7Rs. These data indicate that Cav-1 plays a role
in regulating constitutive 5-HT7R cell surface localization.
As expected from previous work [5], treatment with 5-HT
reduced maximum binding of [3H]5-HT to 5-HT7Rs and
reduced membranous 5-HT7R protein levels, suggesting that
5-HT7Rs are internalized upon agonist stimulation. No addi-tive eﬀects on maximum [3H]5-HT binding to 5-HT7Rs was
found after combined treatment with Cav-1 and 5-HT. This
lack of additivity between Cav-1 siRNA and 5-HT treat-
ments indicate that 5-HT-mediated regulation of the cell sur-
face levels of 5-HT7Rs could involve a Cav-1-dependent
mechanism. We have previously found that cholesterol
depletion reduces maximum [3H]5-HT binding to 5-HT7Rs
[12]. In the present study, we found no additive eﬀect of
MbCD, that sequester cholesterol, on 5-HT and Cav-1 med-
iated reduction in [3H]5-HT binding to 5-HT7Rs. These data
indicate that 5-HT7Rs are internalized via mechanisms that
are shared by caveolae and cholesterol-enriched lipid rafts.
The presence of such pathways has previously been sug-
gested [19,21]. More evidence for an involvement of lipid
rafts in reducing [3H]5-HT binding to 5-HT7Rs comes from
the observation that genistein, a tyrosine kinase inhibitor
that counteracts lipid raft-mediated endocytosis [19], attenu-
ated 5-HT-mediated reduction of [3H]5-HT binding to 5-
HT7Rs. These data are consistent with reports showing that
stimulation of 5-HT receptors can activate tyrosine kinases
(e.g. [22,23]). In contrast, treatment with sucrose, that inhib-
its clathrin-dependent endocytosis [20], had no eﬀect on 5-
HT-mediated reduction of [3H]5-HT binding to 5-HT7Rs.
Altogether our data indicate that 5-HT-mediated actions
on cell surface expression of 5-HT7Rs in HeLa cells involves
a caveolae/raft-dependent endocytosis pathway that is inde-
pendent on clathrin [9,21].
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experiments each performed in duplicate (n, control; m, 5-HT; .,
genistein; ¤, genistein/5-HT). (B) Bmax analysis of the [3H]5-HT
binding to 5-HT7Rs showing that treatment with genistein has no eﬀect
by itself but inhibits 5-HT-mediated actions. **P < 0.01 versus control
using one-way ANOVA followed by Newman–Keul’s post hoc test.
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Fig. 7. Sucrose treatment has no eﬀect on [3H]5-HT binding to 5-
HT7Rs. (A) Saturation binding curves showing the means ± S.E.M.
from four experiments each performed in duplicate. (n, control; m, 5-
HT; ., sucrose; ¤, sucrose/5-HT). (B) Bmax analysis of the [3H]5-HT
binding to 5-HT7Rs. ***P < 0.001 versus control using one-way
ANOVA followed by Newman–Keul’s post hoc test.
5120 B. Sjo¨gren, P. Svenningsson / FEBS Letters 581 (2007) 5115–5121It should be noted that these experiments were performed in
cells expressing the 5-HT7(a)R isoform. It has previously been
demonstrated that the various isoforms of 5-HT7Rs show
similar binding and signaling properties, but diﬀerent internal-
ization pattern [24]. The 5-HT7(a) and 5-HT7(b) isoforms are
internalized in response to agonist stimulation. In contrast,
the 5-HT7(d) isoform is constitutively internalized independent
on agonist stimulation and can, in fact, be internalized in
response to an antagonist. Further studies are required to
determine whether there are diﬀerences in the involvement of
Cav-1 in regulating cell surface levels of various 5-HT7R iso-
forms.
In agreement with the general view on agonist stimulation of
GPCRs [25], 5-HT treatment lowered the aﬃnity of [3H]5-HT
to 5-HT7Rs, probably reﬂecting an altered G protein-coupling
of the receptor. Cav-1 siRNA did not counteract the agonist-
induced lowering of aﬃnity of [3H]5-HT towards 5-HT7Rs,
indicating a lack of participation in Cav-1 in this phenomenon.
It has been demonstrated that siRNA-mediated knockdown
of Cav-1 reduces cell surface localization of 5-HT(2A)Rs [26].
Here, we show that cell surface levels of not only 5-HT2ARs,
but also 5-HT7Rs, is regulated by Cav-1. Moreover, further
evidence for a role of cholesterol-enriched lipid rafts in regulat-
ing cell surface expression of 5-HT7Rs is provided.Acknowledgement: This study was supported by Vetenskapsra˚det, Tor-
sten och Ragnar So¨derberg’s stiftelse and Hja¨rnfonden.References
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